TICLID (ticlopidine hydrochloride) by Roche is clinical pharmacology mechanism of action when taken orally, ticlopidine hydrochloride causes a time- and dose-dependent inhibition of both platelet aggregation and release of platelet granule constituents, as well as a prolongation of bleeding time. First approved in 1991.
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
TICLID (ticlopidine hydrochloride) is an oral antiplatelet agent that inhibits ADP-induced platelet aggregation and prolongs bleeding time through irreversible platelet membrane inhibition. It is used to reduce thrombotic events in patients at risk for stroke, myocardial infarction, or other ischemic complications. The drug achieves maximum platelet inhibition after 8–11 days of twice-daily dosing.
Product is approaching loss of exclusivity with limited linked job openings, indicating a contracted or transitional commercial organization focused on managed decline.
CLINICAL PHARMACOLOGY Mechanism of Action When taken orally, ticlopidine hydrochloride causes a time- and dose-dependent inhibition of both platelet aggregation and release of platelet granule constituents, as well as a prolongation of bleeding time. The intact drug has no significant activity at…
Worked on TICLID at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TICLID represents a late-career or transition opportunity rather than a growth role; the product generates minimal hiring activity and is managed primarily for cost efficiency and compliance. Career development is limited to maintaining existing market share, managing generic conversion, and supporting legacy patient populations rather than pursuing innovation.